Latham advises Cheplapharm on 390m note placement

Latham & Watkins advised Cheplapharm Arzneimittel, a European company focused on well-established medicines, on a private placement of 390 million senior secured notes.

Deal details

The placement follows Cheplapharm’s recently announced 1.2 billion term loan B financing and its strategic partnership with Sanofi. Latham & Watkins advised Cheplapharm on both of those transactions as well.

Latham team

The Latham team was led by Rüdiger Malaun, capital markets partner in Munich, and Jan Penselin, capital markets partner in Frankfurt. They were supported by associates Peter Neuböck and Tobias Müller. Ulf Kieker, partner in Munich, provided advice on tax matters.

Pictured: Rüdiger Malaun (left) and Jan Penselin (right)